Targeted Therapies for Myeloma and Metastatic Bone Cancers
Abstract
Developed two procedures for preparing nanoparticles and demonstrated their ability to repeatedly produce nanoparticles with narrow distribution in the target particle size range of 70-200nm and smaller, if necessary. Synthesized and fully characterized PLA-b-PEG-Maleimide block copolymers to facilitate the attachment of bone-targeting ligands to polymer nanoparticles via thiol coupling. Improved lyostability of polymer nanoparticles, with and without PEG modification. Developed methods to radiolabel polymer nanoparticles, the first time, to our knowledge, this has been done. Encapsulated two proteasome inhibitors, MG-132 and PS-1, and determined their in vitro release profiles. Developed proteasome activity assay to determine activity of encapsulated drug. Developing in vitro assay to determine affinity of bone-targeting nanoparticles to hydroxyapatite substrates.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2007
- Accession Number
- ADA467829
Entities
People
- Neal Vail
Organizations
- Southwest Research Institute